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Abstract
Purpose—World Trade Center (WTC) exposure caused airflow obstruction years after exposure. 
Chitinases and IgE are innate and humoral mediators of obstructive airway disease. We 
investigated if serum expression of chitinases and IgE early after WTC exposure predicts 
subsequent obstruction.
Methods—With a nested case-control design, 251 FDNY personnel had chitotriosidase, YKL-40 
and IgE measured in serum drawn within months of 9/11/2001. The main outcome was subsequent 
Forced Expiratory Volume after one second/Forced Vital Capacity (FEV1/FVC) less than the 
lower limit of normal (LLN). Cases (N=125) had abnormal FEV1/FVC whereas controls had 
normal FEV1/FVC (N=126). In a secondary analysis, resistant cases (N=66) had FEV1 (≥107%) 
one standard deviation above the mean. Logistic regression adjusted for age, BMI, exposure 
intensity and post-exposure FEV1/FVC modeled the association between early biomarkers and 
later lung function.
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Results—Cases and Controls initially lost lung function. Controls recovered to pre-9/11 FEV1 
and FVC while cases continue to decline. Cases expressed lower serum chitotriosidase and higher 
IgE levels. Increase in IgE increased the odds of airflow obstruction and decreased the odds of 
above average FEV1. Alternately, increasing chitotriosidase decreased the odds of abnormal 
FEV1/FVC and increased the odds of FEV1≥107%. Serum YKL-40 was not associated with 
FEV1/FVC or FEV1 in this cohort.
Conclusions—Increased serum chitotriosidase reduces the odds of developing obstruction after 
WTC-particulate matter exposure and is associated with recovery of lung function. Alternately, 
elevated IgE is a risk factor for airflow obstruction and progressive lung function decline.
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INTRODUCTION
World Trade Center (WTC)-particulate matter (PM) exposure from the 9/11 disaster resulted 
in significant airflow obstruction and reactive airway disease in Fire Department of New 
York (FDNY) rescue workers, other exposed workers, lower Manhattan residents and 
children (1–7). A recent longitudinal study by FDNY reported that exposure to WTC dust 
led to a dramatic decline in forced expiratory volume in one second (FEV1) of FDNY rescue 
workers during the first year after exposure without subsequent recovery in a majority of 
those exposed (8). A minority of those exposed had accelerated decline of lung function 
suggesting greater than average susceptibility to lung injury (1, 8). Alternately, another 
subgroup recovered of FEV1 suggesting greater than average resistance to the long-term 
effects of PM exposure (9). It is unclear why some individuals’ lung function improved 
while others’ continued to deteriorate. We therefore characterized biomarkers of resistance 
and susceptibility to WTC PM-related lung injury. We previously described a set of 
biomarkers of inflammation, metabolic syndrome and vascular injury in serum collected 
within six months of 9/11/2001 that predicted future decline or improvement in FEV1 (9–
11).
The ratio of FEV1/Forced Vital Capacity (FVC) is another well-validated spirometric 
measure. Reduction of FEV1/FVC indicates airflow obstruction that characterizes COPD 
and asthma. Genome wide association studies (GWAS) observed that a set of genetic 
variants are associated with only FEV1, variation at other loci predict only FEV1/FVC and 
variation at a third set of loci is associated with both FEV1 and FEV1/FVC (12, 13). This 
suggests independent but overlapping regulation of FEV1 and FEV1/FVC in health and 
disease. Biomarkers predicting abnormal FEV1/FVC may therefore be distinct from FEV1. 
Hence, we investigated if biomarkers expressed within 6 months of 9/11/2001 predicted 
future abnormal FEV1/FVC in this WTC exposed cohort.
The glycosyl hydrolase 18 gene family contains true chitinases that bind and cleave chitin. 
Other chitinase-like proteins (CLP) bind but do not cleave the chitin polysaccharide. Among 
these chitinases/CLPs, chitotriosidase is the major enzymatically active chitinase in humans 
and the best characterized chitinase from a biologic and clinical perspective (14, 15). 
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Chitotriosidase is part of the innate host defense against bacterial and fungal infections since 
chitin is a major structural component in bacteria, fungi, insects and crustaceans, but not in 
mammals (16–20). YKL-40 is a CLP that is strongly associated with human diseases 
characterized by inflammation, remodeling and fibrosis (21–25). However, its biological 
function has not been clearly defined. Chitotriosidase is produced in mature monocyte-
derived macrophages, lung macrophages and other specific subsets of tissue macrophages 
(26–29). Elevated chitotriosidase expression is associated with smoking induced and fibrotic 
lung disease (30, 31). The utility of chitotriosidase or YKL-40 as biomarkers of lung disease 
is under active investigation. However, their utility in particulate matter induced airway 
obstruction has not been elucidated.
Immunoglobulin E (IgE)-mediated humoral immunity is another important immune 
response mechanism in the respiratory tract (32). Elevated IgE is a key immune mediator in 
asthma. Children and adults with asthma have higher IgE than normal controls and anti-IgE 
antibody is an effective asthma treatment (33–36). Elevated serum IgE is strongly associated 
with low FEV1/FVC in patients with chronic obstructive lung disease (37).
Our studies have focused on the well phenotyped WTC exposed FDNY firefighter cohort. 
The intense PM exposure at the WTC site overwhelmed the lung’s normal protective 
barriers. We hypothesized that particulate matter exposure-induced lung injury is associated 
with immune mediators of asthma and COPD. We tested if serum chitinases and IgE, 
expressed soon after a massive PM exposure predict subsequent airway obstruction.
METHODS
Study design
We preformed a nested case-control study using a homogeneous previously healthy baseline 
cohort of 801 WTC exposed rescue and recovery workers. The study group did not contain 
individuals with lung disease or tobacco use to eliminate these confounders. The baseline 
cohort was derived from 1,720 exposed workers who needed subspecialty pulmonary 
evaluation (SPE) and treatment within 6.5 years of 9/11/2001. The study cohort was derived 
from three subgroups of the baseline cohort: 1) A randomly selected a subgroup to represent 
biomarker expression in the total cohort (171/801). 2) Those with the worst FEV1 at SPE 
(100/801) to represent those susceptible to WTC induced lung injury. 3) Those with the best 
FEV1 at SPE (100/801) to represent those resistant to lung injury (9). Serum was available 
in 124/171 of the representative subgroup, 66/100 of the resistant subgroup and 68/100 of 
the susceptible subgroup. Since there was overlap between subgroups, the study group was 
251/801 of the baseline cohort. Cases were defined by FEV1/FVC less than lower limit of 
normal (LLN, N=125) at SPE, whereas controls had FEV1/FVC greater than LLN (N=126).
Demographics
Age, race and years of service at FDNY were obtained from the FDNY-WTC-monitoring 
database. BMIs were calculated from height and weight measured at the time of medical 
monitoring evaluation (MME) and SPE. Degree of exposure was self-reported at the first 
FDNY-WTC-monitoring and was categorized using the FDNY-WTC Exposure Intensity 
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Index (Arrival Time): i. Presented on the morning of 9/11/2001 ii. Arrived between 
afternoon on 9/11/2001 and 9/12/2001 (9–11). Those arriving after day three were excluded 
from analysis as a result of their low numbers in this sample.
Serum Sampling and Analysis
Blood drawn at the first post-9/11 FDNY-WTC monitoring exam was allowed to stand for 
one hour at room temperature before being centrifuged at 1,800g for ten minutes. Serum was 
stored at −80°C (Bio-Reference Laboratories, Inc. Elmwood Park, NJ). Serum was thawed 
once at four degrees and assayed using chitotriosidase (Quidel, USA), YKL-40 (MicroVue, 
USA) and IgE (R&D, Minnesota, USA) ELISA panels according to manufacturer’s 
instructions. Data was analyzed using Graphpad Prism V (San Diego, USA).
Statistical Analysis
We tested normality using the Shapiro-Wilk test and Q-Q plots. We used unpaired Student’s 
t-test or Wilcoxon rank-sum test for between group comparisons, as appropriate. Chi-
squared test was used for inferences on proportions.
Given the dichotomous outcome of normal and abnormal FEV1/FVC ratio, we tested if 
serum biomarkers predicted airflow obstruction using logistic regression. In addition to 
demographic variables, we tested if FEV1/FVC ratio at the time serum was drawn altered the 
biomarker disease association. Equivalent analysis was done with the dichotomous outcome 
of FEV1.
The Hosmer-Lemeshow goodness-of-fit test was used to assess calibration of the model. The 
model discrimination was evaluated through the receiver operating characteristic area under 
the curve (AUC). To test the robustness of the models, internal validation was performed 
using bootstrap procedures (10,000 bootstrap samples). Data are expressed as mean 
(standard deviation, SD), median (interquartile range, IQR) or Odds Ratio (95% confidence 
interval), unless otherwise stated. A two-sided P-value less than 0.05 was considered 
significant. All analyses were performed with STATA/SE version 12.1 (StataCorp LP, 
College Station, TX) and SPSS version 20 (IBM, USA).
Results
Demographics
Derivation of cases and controls is described in Figure 1. The demographics of baseline 
cohort, the study cohort, cases and controls are shown in Table 1. A study cohort of 251/801 
had biomarkers measured in serum drawn soon after 9/11 during the first medical 
monitoring exam (MME). The median time to the serum draw at MME was 2.6 months post 
9/11. The baseline cohort, study cohort, cases and controls had no significant difference in 
the time post 9/11 that serum biomarkers were measured.
Case status was defined by FEV1/FVC ratio at subsequent subspecialty pulmonary 
evaluation (SPE). Cases of airflow obstruction (125/251) have had an abnormally low 
FEV1/FVC ratio at SPE, while controls (126/251) have a normal ratio. The median time to 
SPE was 33.8 months post 9/11. The baseline cohort, study cohort, cases and controls had 
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no significant difference in the time post-9/11 that FEV1/FVC was measured. Cases and 
controls had similar WTC exposure intensity, BMI and racial distribution. Cases were two 
years younger at 9/11 and had 2.2 less years of firefighting service than controls (P<0.01).
Pulmonary Function
By design, cases and controls were markedly different from one another in FEV1/FVC ratio 
34 months after 9/11/2001 on SPE spirometry (0.73 vs 0.82, Table 2). Cases and controls 
were also different from one another in pre-9/11 ratio (0.82 vs 0.87 P<0.001) and ratio at 
MME (0.81 vs 0.87 P<0.001). In a longitudinal analysis, the FEV1/FVC ratio did not change 
in cases or controls from pre-9/11 spirometry to MME. In the interval from MME to SPE, 
the ratio declined in both cases (0.81 to 0.73 P<0.001) and controls (0.87 to 0.82 P<0.01) but 
cases had more deterioration than controls. To confirm that the median FEV1/FVC in cases 
and controls represented individual deterioration, we used patients as their own control 
subjects. The mean individual reduction of the ratio from 9/11 to SPE was 9% (P=0.019) in 
cases and 4% in controls (P<0.001).
Similar to FEV1/FVC ratio, FEV1 % predicted was consistently lower in cases than controls 
at all time points. Surprisingly, in longitudinal analysis, cases lost 7% of their pre-9/11 
FEV1 while controls lost 11% at MME. Cases continued to lose FEV1 from MME to SPE 
(86% to 81%), whereas FEV1 in controls increased between two time points (97% to %108) 
returning to pre-9/11 values. Individual longitudinal lung function demonstrated the mean 
FEV1 increased by 5% from 9/11 to SPE in cases (P=0.019) and decreased by 5% in 
controls (P=0.001). The mean individual FVC increased by 6% in cases (P<0.001) and 8% 
in controls (P<0.001).
At the time of SPE, cases had more air trapping and airway reactivity than controls. Cases 
had higher residual volume (RV) than controls (130% vs 111% P<0.001) without changes in 
functional residual capacity (FRC) or diffusing capacity for carbon monoxide (DLCO). 
Cases had more airway reactivity defined by FEV1 increase in response to bronchodilator (9, 
IQR 4–16 in cases vs 4, IQR 0–8 in controls P<0.001) and FEV1 decline in response to 
methacholine (MCT slope of cases 0.092, IQR 0.04–0.42 vs controls 0.038, IQR 0.02–0.07 
P<0.001).
Serum Biomarkers
A total of 251 cases and controls had serum chitotriosidase, YKL-40 and IgE measured an 
average of 3 months after September 11, 2001. Compared to controls, cases had significant 
reduction of chitotriosidase (24.5ng/mL vs 32.2ng/mL, P<0.001) and significant elevation of 
IgE (50IU/mL vs 35.7IU/mL, P=0.01) (Table 3). There was no difference in YKL-40 
between cases and controls (41.0ng/mL vs 44.0ng/mL, P=0.621). The range of 
chitotriosidase concentration was 1 to 174ng/mL and the range of IgE was 1.47 to 641IU/ml. 
Since the major source of chitotriosidase is phagocytes, we assessed if controls and cases 
had different leukocyte concentrations and differentials to rule out confounding effect. There 
was no significant difference in total leukocyte concentration, absolute neutrophil count and 
absolute lymphocyte count (P=0.549, 0.942 and 0.057 respectively) between cases and 
controls.
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Logistic model predicting abnormal FEV1/FVC
In an initial series of univariable analysis we observed significant association of abnormal 
FEV1/FVC ratio at SPE with chitotriosidase, IgE, age and FEV1/FVC ratio at the time serum 
was drawn. Increasing age, chitotriosidase and FEV1/FVC ratio at MME reduced the odds of 
abnormal FEV1/FVC ratio at SPE while increasing IgE increased the odds of airflow 
obstruction (Table 4). There was no association between YKL-40 and airflow obstruction 
(data not shown). In this small cohort, there was no significant association of WTC exposure 
intensity or BMI with abnormal FEV1/FVC ratio at SPE (Table 4).
Multivariable logistic regression analysis showed that the biomarker-disease association 
remained after adjusting the model for potential confounders (Table 4). For each 10ng/mL 
increase of serum chitotriosidase the odds airflow obstruction at SPE declined by 18% 
(95%CI: 0.71, 0.95). We added the range of chitotriosidase to the adjusted logistic model 
and calculated the probability of abnormal FEV1/FVC ratio (Figure 2). When holding all 
other variables in the model constant the probability of obstruction declined from 60.2% to 
15.5% as the concentration of chitotriosidase increased from 1 to 174ng/mL (Figure 2 panel 
A). For each 100IU/mL increase of IgE, the odds of having a FEV1/FVC less than LLN 
increased by 36% (95%CI: 1.09, 1.71). The probability of obstruction increased from 44.8% 
to 74.9% as the concentration of IgE increased from 1.47 to 641IU/mL (Figure 2 panel B). 
We then used receiver operating characteristic analysis to assess the sensitivity and 
specificity of the model for predicting airflow obstruction. The model had excellent 
performance with an AUC of 0.86 (Figure 2 panel C). The interaction term between 
chitotriosidase and IgE was not significant (data not shown).
FEV1 as an outcome
FEV1 is another well-validated spirometric measure to identify airway obstruction (9). We 
repeated the analysis with 66 individuals who had FEV1≥107% at SPE. These cases 
represent individuals with above average lung function who were resistant to the damaging 
effects of WTC exposure. We have previously reported the demographics and PFT of these 
resistant cases (9). Resistant cases had higher chitotriosidase than controls (26.2ng/mL vs 
35.3ng/mL, P=0.007) and significant reduction of IgE (50.0IU/mL vs 35.7IU/mL, P=0.026). 
There was no difference in YKL-40 between cases and controls (43.2ng/mL vs 41.8ng/mL, 
P=0.621). For each 10ng/mL increase of serum chitotriosidase the odds of being in resistant 
group at SPE increased by 14% (95%CI: 1.012, 1.292). There was no association between 
YKL-40 and improvement in lung function after WTC exposure (95% CI: 0.991, 1.009). For 
each 100 IU increase in IgE the OR for resistance was 0.887 (95% CI: 0.71, 1.11). In 
addition, we tested if previously reported biomarkers of FEV1 (9–11) were correlated with 
chitotriosidase or IgE. There was significant correlation between chitotriosidase and soluble 
vascular cell adhesion molecule (sVCAM) (R=0.197, P=0.002). Macrophage-derived 
chemokine (MDC), granulocyte-macrophage colony-stimulating factor (GM-CSF), leptin, 
amylin, ApoAII, C-reactive protein (CRP), mMacrophage inflammatory protein (MIP) were 
not associated with either chitotriosidase or IgE.
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The WTC collapse produced a massive acute exposure to PM leading to a 439mL reduction 
of FEV1 over the first six months in never smoking firefighters (8). FVC declined in parallel 
producing a pseudo-restrictive pattern on spirometry that was due to air trapping (38). Some 
individuals recovered while others had progressive lung function decline. To better 
understand intrinsic susceptibility and resistance to the damaging effects of WTC exposure 
we conducted a series of nested case-control studies (9–11). The study cohort was 801 never 
smokers with normal pre-9/11 lung function who sought subspecialty pulmonary evaluation 
(SPE) prior to March 2008. We have reported that levels of serum biomarkers of 
inflammation, metabolic syndrome and cardiovascular risk expressed within 6 months of 
September 11, 2011 were associated with increased risk of abnormal FEV1 years later, with 
higher levels of some associated with increased risk and others associated with reduced risk. 
We now report early elevation of serum chitotriosidase reduces the risk of airway 
obstruction defined by abnormal FEV1/FVC. It also predicts above average FEV1 in the 
years following WTC exposure. Therefore chitotriosidase is a biomarker of resistance to 
lung injury. Alternately elevated IgE is a risk factor for abnormal FEV1/FVC and reduces 
the odds of above average lung function post WTC exposure. Finally, there was no 
association of YKL-40 and any measure of lung function. This suggests that YKL-40 
regulation in PM-induced asthma is significantly different than YKL-40 in allergic asthma 
(21–25).
The study cohort was nested within a larger, longitudinally followed population of 
symptomatic FDNY firefighters who were exposed to particulate matter from the WTC 
disaster. We narrowed 1720 subjects to a baseline cohort of 801 individuals. We chose to 
exclude active and prior smokers to eliminate a major confounder of abnormal lung function 
and chitotriosidase expression (30).
This investigation used FEV1/FVC and FEV1 as two separate outcomes in the analysis. We 
chose FEV1/FVC below LLN to define lung injury since this cut point is derived from large 
cross sectional population studies. We chose FEV1≥107% to define resistance to lung injury 
since this value is one standard deviation above the mean at SPE in this WTC exposed 
cohort. Prior studies of this cohort used only FEV1 as a measure of susceptibility or 
resistance to lung injury. Adding an explicit measure of airflow obstruction to the analysis 
enabled us to overcome the limitations of using of FEV1 as a single measure of lung injury 
in this cohort. Using only FEV1 can result in misclassification of disease since FEV1 is 
reduced in both restrictive and obstructive lung disease. Furthermore patients who starting 
with pre-9/11 FEV1 well above 107%, could suffer large, clinically significant decline in 
FEV1 and remain above the cut point defining resistance to lung injury. Therefore FEV1/
FVC, when used in conjunction with FEV1, provides a more complete measure of the 
resistance and susceptibility to the damaging effects of WTC exposure.
Both serum chitotriosidase and IgE expressed early after exposure are biomarkers for 
abnormal FEV1/FVC and above average FEV1 years later. The concept that FEV1/FVC and 
FEV1 may reflect distinct but overlapping pathophysiologic mechanisms of lung disease is 
supported by GWAS findings (12, 13). Some genetic polymorphisms are associated with 
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both FEV1 and FEV1/FVC, whereas other variants are associated with one or the other. To 
date chitotriosidase and IgE are the only biomarkers that predict susceptibility or resistance 
to FEV1/FVC. Previously reported biomarkers of FEV1(9–11); MDC, GM-CSF, leptin, 
amylin and apolipoproteins are not associated with airflow obstruction.
Patients with normal FEV1/FVC and above average FEV1 years after WTC exposure had 
higher serum chitotriosidase than controls. Multivariable logistic regression showed that 
patients with increased serum chitotriosidase soon after exposure had significantly reduced 
odds of subsequent airflow obstruction defined by abnormal FEV1/FVC. They also had 
increased odds of above average FEV1. In fact, these resistant individuals returned to their 
pre-9/11 FEV1 and FVC on average 32 months post-9/11. Chitotriosidase is therefore a 
biomarker of recovery from lung injury. This suggests the group with high chitotriosidase 
levels had the capacity to repair irritant induced lung injury. We have previously observed 
sVCAM also predicts average FEV1. Interestingly sVCAM expression and chitotriosidase 
expression are correlated raising the possibility that they are separate components of 
protective pathways.
Our nested case-control biomarker study has the advantage that serum biomarkers were 
measured on average 3 months after the acute exposure during the process of disease 
evolution. The outcome occurred on average 32 months after exposure. Because the 
biomarkers were measured prior to case definition it is unlikely that its expression is a 
consequence of good outcome. Chitotriosidase plays an important role in innate immunity 
and is associated with smoking, sarcoidosis, pulmonary infections, as well as interstitial lung 
disease (30, 31, 39–42). These cross sectional studies are unable to distinguish if elevated 
chitotriosidase cause disease, are a reparative response to disease or are a consequence of 
disease with no impact on lung function. The potential mechanism of chitotriosidase’s role 
in protecting from WTC-PM induced lung injury is unknown. Our data are consistent with 
the hypothesis that chitotriosidase plays a beneficial role in injury repair after WTC-PM 
induced lung. Testing this hypothesis requires experiments in model systems in combination 
with larger longitudinal studies.
In contrast to chitotriosidase, IgE is critical for humoral immune function in the lung. IgE’s 
association with airway obstruction and atopy is well known (32–37). As expected, 
increased IgE predicted subsequent airway obstruction in our WTC exposed cohort. We also 
observed that increasing IgE reduced the odds of above average FEV1 post exposure. 
Importantly, no member of this cohort had atopic asthma prior to exposure since the 
presence of asthma precludes active firefighting duty. Also most of the population had IgE 
levels in the normal range. IgE’s association with WTC-PM induced lung injury implies a 
complex pathophysiologic response to irritant induced lung injury reflected in the humoral 
immune system. Further investigation is required to assess if antigen specific antibodies are 
responsible for the observed phenotype or variation of IgE within the normal range reflects 
other attributes of the immune response to respiratory irritants that increases the risk for lung 
injury.
This study has several limitations. Our FDNY firefighters cohort is unique as they had 
massive acute exposure to WTC dusts. This limits the generalizability of these finding to 
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other study populations with lower level PM exposure produced by ambient air pollution. 
We did not have an unexposed control group to compare and therefore we could not 
determine the direct effect of WTC-PM exposure on chitotriosidase or IgE levels. 
Replication of these findings in other longitudinally followed populations with and without 
PM exposure will be important to demonstrate the generalizability of these findings.
In this study, increased serum chitotriosidase levels reduced the risk of developing airway 
obstruction after WTC-PM exposure and predicted above average FEV1 post exposure. 
Alternately, elevated IgE was a risk factor for abnormal FEV1/FVC and reduced the odds of 
above average FEV1. These results suggest that both innate and humoral immune mediators 
are involved in the pathogenesis of WTC-PM mediated lung injury. Further investigation is 
required to define if chitotriosidase is a mediator of lung repair after PM exposure.
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Study design. WTC=World Trade Center; FDNY=Fire Department City of New York; 
NHANES=National Health and Nutrition Examination Survey; PFT=Pulmonary Function 
Test
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Final logistic model prediction A. Calculated probability of FEV1/FVC<LLN with 95% CI 
as the concentration of chitotriosidase increased over the observed biomarker range with all 
other covariates held constant. B. Calculated probability of FEV1/FVC<LLN as IgE 
increases C. Receiver operating characteristic (ROC) of the final model to predict abnormal 
FEV1/FVC. Area under the curve (AUC)=0.86.
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Table 1
Demographics
Baseline Cohort N=801 Study Group N=251 Controls N=126 Cases N=125
High WTC Exposure*‡ 197 (25) 52 (21) 30 (24) 22 (18)
Intermediate WTC Exposure†‡ 604 (75) 199 (79) 96 (76) 103 (82)
Months to MME§ 2.7 (2–3.8) 2.6 (2.1–3.3) 2.6 (2.1–3.3) 2.7 (2.1–3.7)
Months to SPE§ 33.8 (25–57) 33.6 (24–54) 32.0 (24–53) 35.5 (24–57)
BMI at MME, kg/m2 § 28.0 (26–30) 27.9 (26–30) 27.6 (26–30) 28.1 (26–31)
BMI at SPE, kg/m2 § 28.9 (27–31) 28.8 (27–31) 28.5 (26–31) 29.1 (27–31)
Age at hire, years§ 27 (24–29) 27 (25–29) 27 (25–30) 27 (25–29)
Age at 9/11, years§ 40 (36–45) 41 (37–46) 42 (38–46) 40 (36–45) ll
Years of Service at 9/11§ 13.9 (7–19) 14.5 (8–18) 15.3 (10–20) 13.1 (7–17) ll
Race, Caucasian/African American‡ 782 (98)/19 (2) 242 (96)/9 (4) 121 (96)/5 (4) 121 (97)/4 (3)
Definition of abbreviations: WTC = World Trade Center; MME = medical monitoring entry; SPE = subspecialty pulmonary evaluation; BMI = 
body mass index.
*
Arrival at WTC 9/11 Morning,
†
Arrival at WTC between noon of 9/11 and midnight of 9/12.
‡
Expressed as N (%);
§
Values Expressed as Medians (IQR);
ll
p<0.01 by Wilcoxon rank-sum test between cases and controls.
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Table 3
Serum Levels of Analytes
Serum Analyte Total Controls Cases P-value*
Chitotriosidase (ng/mL) 29.9 (18–46) 32.2 (20–52) 24.5 (15–40) <0.001
IgE (IU/mL) 44.6 (17–116) 35.7 (11–81) 50 (24–148) 0.010
YKL-40 (ng/mL) 42.1 (30–61) 41.0 (31–65) 44.0 (30–59) 0.621
All Values Expressed as Median (IQR);
*
Significance assessed by Wilcoxon rank-sum test between cases and controls.
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Table 4
Analysis Predicting FEV1/FVC<LLN at SPE
Model Predictor OR (95% CI)
Univariable
Age (yr) 0.94 (0.90, 0.98)
BMI (kg/m2) 1.02 (0.97, 1.08)
Exposure High* 0.68 (0.40, 1.27)
FEV1/FVC at MME 0.78 (0.72, 0.83)
Chitotriosidase† 0.84 (0.75, 0.94)
IgE‡ 1.23 (1.01, 1.50)
Multivariable§
Chitotriosidase† 0.82 (0.71, 0.95)
IgE‡ 1.36 (1.09, 1.71)
Definition of abbreviations: LLN = lower limit of normal; SPE = subspecialty pulmonary evaluation; OR = odds ratio; BMI = body mass index; 
MME = medical monitoring evaluation.
*
Reference is intermediate exposure group.
†
10 ng/mL of Chitotriosidase
‡
100 IU/mL of IgE.
§
Adjusted for age at 9/11/2001, BMI at SPE, exposure group and FEV1/FVC at MME. χ2 (6) = 49.465, P = <0.001. Hosmer and Lemeshow’s 
goodness-of-fit test P=0.588. Area under ROC curve=0.86.
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